Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2016-08-28T12:08:36Z | - |
dc.date.available | 2016-08-28T12:08:36Z | - |
dc.date.issued | 2009 | * |
dc.identifier.issn | 0928-0987 | * |
dc.identifier.other | OAK-6120 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/220401 | - |
dc.description.abstract | Levodopa (l-dopa), the metabolic precursor of dopamine, has primarily been used for the treatment of Parkinson's disease (PD) in combination with carbidopa (C-dopa). This study aims to investigate the feasibility of l-dopa nasal delivery systems prepared using maleic acid solution containing 2-hydroxypropyl-β-cyclodextrin, and to develop pharmacokinetic models. Following oral or intravenous administration of l-dopa plus C-dopa and intranasal dosing of l-dopa in the presence and absence of C-dopa to the rat, the concentrations of l-dopa in plasma and brain were determined using HPLC. The pharmacokinetic profiles were analyzed using non-compartmental and compartmental modeling approaches. Simultaneous nonlinear regression was performed to improve the identifiability of model parameters. l-Dopa was rapidly absorbed into blood and brain. The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively. C-dopa caused a 1.2-fold decrease in the elimination rate of l-dopa, indicating decreased metabolism. Although the half-life after nasal administration was relatively short (less than 30 min) in both blood and brain regardless of C-dopa addition, the systemic exposure was promising due to rapid absorption. In conclusion, the l-dopa nasal delivery system could be used as a good rescue therapy for PD patients who experience symptom fluctuation with oral l-dopa administration. © 2009 Elsevier B.V. All rights reserved. | * |
dc.language | English | * |
dc.title | Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 38 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 525 | * |
dc.relation.lastpage | 532 | * |
dc.relation.journaltitle | European Journal of Pharmaceutical Sciences | * |
dc.identifier.doi | 10.1016/j.ejps.2009.09.019 | * |
dc.identifier.wosid | WOS:000272572900013 | * |
dc.identifier.scopusid | 2-s2.0-70449521005 | * |
dc.author.google | Kim T.K. | * |
dc.author.google | Kang W. | * |
dc.author.google | Chun I.K. | * |
dc.author.google | Oh S.Y. | * |
dc.author.google | Lee Y.H. | * |
dc.author.google | Gwak H.S. | * |
dc.date.modifydate | 20240422115307 | * |